Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Reaffirmed by Cantor Fitzgerald

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)'s stock had its "overweight" rating restated by analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They currently have a $107.00 price objective on the biopharmaceutical company's stock. Cantor Fitzgerald's price target would suggest a potential upside of 150.29% from the company's current price.

A number of other equities research analysts have also weighed in on RARE. JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an "overweight" rating in a report on Monday, March 18th. Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a "buy" rating in a report on Wednesday, February 21st. Royal Bank of Canada assumed coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They set an "outperform" rating and a $77.00 price objective for the company. Robert W. Baird boosted their price objective on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a research report on Tuesday, January 30th. Finally, TD Cowen increased their price target on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Wednesday, April 24th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $88.00.

Ultragenyx Pharmaceutical Stock Performance

RARE stock traded down $0.45 during midday trading on Friday, hitting $42.75. 1,143,007 shares of the stock were exchanged, compared to its average volume of 767,975. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -5.13 and a beta of 0.68. Ultragenyx Pharmaceutical has a fifty-two week low of $31.52 and a fifty-two week high of $54.98. The stock's 50-day moving average price is $47.25 and its 200-day moving average price is $44.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The company had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. During the same quarter last year, the company posted ($2.33) EPS. Ultragenyx Pharmaceutical's quarterly revenue was up 8.3% compared to the same quarter last year. Research analysts anticipate that Ultragenyx Pharmaceutical will post -6.38 EPS for the current year.

Insider Activity

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the sale, the insider now owns 89,268 shares in the company, valued at $4,799,047.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the sale, the insider now owns 89,268 shares of the company's stock, valued at approximately $4,799,047.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the transaction, the executive vice president now owns 252,823 shares of the company's stock, valued at approximately $12,623,452.39. The disclosure for this sale can be found here. Insiders have sold a total of 32,116 shares of company stock worth $1,645,983 over the last three months. Corporate insiders own 6.80% of the company's stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth $493,000. Capstone Investment Advisors LLC purchased a new stake in Ultragenyx Pharmaceutical in the first quarter worth approximately $227,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Ultragenyx Pharmaceutical by 113.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 230,767 shares of the biopharmaceutical company's stock valued at $10,775,000 after purchasing an additional 122,412 shares during the last quarter. Privium Fund Management B.V. increased its holdings in shares of Ultragenyx Pharmaceutical by 29.2% in the first quarter. Privium Fund Management B.V. now owns 215,102 shares of the biopharmaceutical company's stock worth $10,043,000 after buying an additional 48,596 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Ultragenyx Pharmaceutical by 67.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock valued at $155,000 after acquiring an additional 1,339 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.